by Table of Contents
The global amyloidosis therapeutics market size was valued at USD 2.94 billion in 2024 and is expected to reach around 6.45 billion by 2034, growing at a CAGR of 8.18% from 2025 to 2034.
Get Sample Copy of Report@ https://www.precedenceresearch.com/sample/5710
Key Points
- In 2024, North America led the global market, holding the largest share at 47%.
- The Asia Pacific region is expected to grow at the fastest CAGR between 2025 and 2034.
- Among treatment types, the chemotherapy segment accounted for the highest market share in 2024.
- The transplantation segment is projected to expand at a notable CAGR during the forecast period from 2025 to 2034.
- By end user, hospitals and clinics dominated the market with the largest share in 2024.
- The home care settings segment is expected to witness the fastest growth throughout the forecast period.
AI Impact on the Amyloidosis Therapeutics Market
AI is playing a crucial role in advancing the amyloidosis therapeutics market, enhancing drug discovery, diagnosis, treatment personalization, and patient monitoring. By leveraging machine learning and big data analytics, AI is revolutionizing how amyloidosis is diagnosed and treated.
Faster Drug Discovery and Development
AI accelerates drug discovery by analyzing vast biomedical datasets to identify potential drug candidates for amyloidosis. Machine learning models predict drug efficacy, optimize molecular structures, and reduce the time and cost required for clinical trials. AI-driven simulations also help researchers understand protein misfolding mechanisms, a key factor in amyloidosis progression.
Improved Diagnosis and Early Detection
Amyloidosis is often misdiagnosed due to its complex symptoms. AI-powered diagnostic tools, including deep learning algorithms and medical imaging analysis, enhance early detection by identifying amyloid deposits in organs with higher accuracy. AI-driven biomarker analysis from blood samples also improves diagnostic precision, leading to earlier and more effective interventions.
Personalized Treatment Plans
AI enables precision medicine by analyzing patient data to tailor treatments based on genetic and clinical factors. AI-driven algorithms assess treatment responses, helping doctors choose the most effective therapies for individual patients. This approach minimizes trial-and-error prescribing and improves patient outcomes.
Predictive Analytics for Disease Progression
Machine learning models analyze patient histories and medical records to predict disease progression. AI can identify patterns in disease development, allowing healthcare providers to take proactive measures to slow the condition’s advancement and improve long-term patient care.
Enhanced Remote Monitoring and Patient Care
AI-powered wearable devices and mobile health apps help monitor amyloidosis patients in real time, tracking vital signs and symptoms. AI-driven telemedicine platforms enable remote consultations, ensuring continuous patient care and reducing the need for frequent hospital visits.
Also Read: Nutraceutical Ingredients Market
Market Scope
| Report Coverage | Details |
| Market Size by 2034 | USD 6.45 Billion |
| Market Size in 2025 | USD 3.18 Billion |
| Market Size in 2024 | USD 2.94 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 8.18% |
| Dominated Region | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Treatment, End User, and Regions. |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Market Dynamics
Market Drivers
The amyloidosis therapeutics market is driven by the increasing prevalence of amyloidosis, growing awareness among healthcare professionals, and advancements in diagnostic techniques. The rising geriatric population, which is more susceptible to amyloidosis, is further fueling market growth. Additionally, ongoing research and development efforts, along with the introduction of novel treatment options, are improving patient outcomes and expanding market opportunities.
Market Opportunities
Significant opportunities lie in the expansion of precision medicine and AI-driven drug discovery, which can lead to more targeted and effective treatments. The increasing adoption of biomarker-based diagnostic methods is also creating new avenues for early detection and intervention. Furthermore, the rise of telemedicine and remote patient monitoring solutions presents a promising opportunity for improving patient care and accessibility to treatment.
Market Challenges
One of the major challenges in the amyloidosis therapeutics market is the complexity of the disease, leading to frequent misdiagnoses and delayed treatment. The high cost of therapies, including chemotherapy and targeted treatments, poses a financial burden on patients and healthcare systems. Additionally, limited awareness in developing regions and a lack of specialized healthcare facilities can hinder early diagnosis and timely intervention.
Regional Analysis
North America dominates the amyloidosis therapeutics market due to well-established healthcare infrastructure, increasing research funding, and high awareness levels. Europe follows closely, benefiting from advancements in diagnostics and a strong pharmaceutical industry. The Asia-Pacific region is expected to witness the fastest growth, driven by rising healthcare investments, improving diagnostic capabilities, and increasing prevalence of amyloidosis-related conditions.
Amyloidosis Therapeutics Market Companies
- Alnylam Pharmaceuticals, Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- GSK plc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Merck KGaA
- Novartis AG
- Ionis Pharmaceuticals
Leader’s Announcements
- In March 2025, Ionis Pharmaceuticals Inc., announced the European Union’s approval for Ionis and AstraZeneca’s WAINZUA (eplontersen). Brett P. Monia, Chief Executive Officer, Ionis, said that, “Today’s approval of WAINZUA in Europe offers adults with hereditary transthyretin-mediated amyloidosis with polyneuropathy a new, self-administered treatment option that provides consistent suppression of transthyretin production and improves neuropathy impairment and quality of life. With approvals in North America, UK and now across the EU, we are proud of the continued progress as we and our partner, AstraZeneca, rapidly and effectively deliver WAINZUA to people around the world.”
Recent Developments
- In February 2025, Paradox Immunotherapeutics, a pharmaceutical company developing innovative antibody therapies, secured a $10 million investment in a financing round led by SymBiosis which is an investment firm concentrated on advancing biotherapeutics innovations for serious and life-threatening diseases. The funding will focus on advancing therapies for protein misfolding diseases and accelerating candidates for immunoglobulin light chain amyloidosis (AL amyloidosis) and leukocyte chemotactic factor 2 amyloidosis (LECT2).
- In July 2024, Kisunla which is a first-of-a-kind amyloid plaque removal therapy developed by Eli Lilly and Company for treatment of adults with early symptoms of Alzheimer’s disease and confirmed amyloid pathology received approval from the U.S. FDA.
Segments Covered in the Report
By Treatment
- Chemotherapy
- Immunosuppressive Drugs
- Transplantation
- Supportive Care
- Surgery
- Others
By End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/
